Vitamin B6CAS# 8059-24-3 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 8059-24-3 | SDF | Download SDF |
PubChem ID | 104817 | Appearance | White crystalline powder |
Formula | C8H10NO5P | M.Wt | 231.14 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate | ||
SMILES | CC1=C(C(=NC=C1COP(=O)([O-])[O-])C)O | ||
Standard InChIKey | RBCOYOYDYNXAFA-UHFFFAOYSA-L | ||
Standard InChI | InChI=1S/C8H12NO5P/c1-5-7(4-14-15(11,12)13)3-9-6(2)8(5)10/h3,10H,4H2,1-2H3,(H2,11,12,13)/p-2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Vitamin B6 Dilution Calculator
Vitamin B6 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.3264 mL | 21.6319 mL | 43.2638 mL | 86.5276 mL | 108.1596 mL |
5 mM | 0.8653 mL | 4.3264 mL | 8.6528 mL | 17.3055 mL | 21.6319 mL |
10 mM | 0.4326 mL | 2.1632 mL | 4.3264 mL | 8.6528 mL | 10.816 mL |
50 mM | 0.0865 mL | 0.4326 mL | 0.8653 mL | 1.7306 mL | 2.1632 mL |
100 mM | 0.0433 mL | 0.2163 mL | 0.4326 mL | 0.8653 mL | 1.0816 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Balsalazide
Catalog No.:BCC5225
CAS No.:80573-04-2
- Grifolic acid
Catalog No.:BCN4344
CAS No.:80557-12-6
- Schinifoline
Catalog No.:BCN4343
CAS No.:80554-58-1
- Vitexin 2''-O-(4'''-O-acetyl)rhamnoside
Catalog No.:BCN6740
CAS No.:80537-98-0
- PHTPP
Catalog No.:BCC7447
CAS No.:805239-56-9
- 7beta-(3-Ethyl-cis-crotonoyloxy)-1alpha-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone
Catalog No.:BCN7638
CAS No.:80514-14-3
- Cis-N-Feruloyltyramine
Catalog No.:BCN3729
CAS No.:80510-09-4
- Grossamide
Catalog No.:BCN4571
CAS No.:80510-06-1
- Euchrestaflavanone A
Catalog No.:BCN3576
CAS No.:80510-05-0
- Veratrine
Catalog No.:BCN8444
CAS No.:8051-02-3
- Glaucocalyxin B
Catalog No.:BCN8440
CAS No.:80508-81-2
- Tenacigenin B
Catalog No.:BCN4342
CAS No.:80508-42-5
- 2',5,6',7-Tetrahydroxyflavanone
Catalog No.:BCN4345
CAS No.:80604-16-6
- 2',5,6',7-Tetraacetoxyflavanone
Catalog No.:BCN4346
CAS No.:80604-17-7
- 8-Demethylsideroxylin
Catalog No.:BCN3117
CAS No.:80621-54-1
- Rifaximin (Xifaxan)
Catalog No.:BCC3848
CAS No.:80621-81-4
- Sanggenone C
Catalog No.:BCN6350
CAS No.:80651-76-9
- Fuziline
Catalog No.:BCN2822
CAS No.:80665-72-1
- Dihydroergotoxine mesylate
Catalog No.:BCC6671
CAS No.:8067-24-1
- 5-O-methylvisamminol
Catalog No.:BCC8108
CAS No.:80681-42-1
- Sec-O-Glucosylhamaudol
Catalog No.:BCN1233
CAS No.:80681-44-3
- Prim-O-glucosylcimifugin
Catalog No.:BCN4952
CAS No.:80681-45-4
- 4'-Demethoxypiperlotine C
Catalog No.:BCN6495
CAS No.:807372-38-9
- Z-Arg(Mtr)-OH.CHA
Catalog No.:BCC3062
CAS No.:80745-09-1
Prospective cohort studies of dietary vitamin B6 intake and risk of cause-specific mortality.[Pubmed:29764693]
Clin Nutr. 2018 May 4. pii: S0261-5614(18)30167-5.
BACKGROUND & AIMS: Vitamin B6 has been postulated to play an important role in determining chronic diseases. However, few studies have evaluated associations between dietary Vitamin B6 and cause-specific mortality comprehensively. METHODS: We investigated the associations between Vitamin B6 from diet and risk of all-cause, and cause-specific mortality in 134,480 participants from the Shanghai Men's Health Study (2002-2014) and Shanghai Women's Health Study (1997-2014). The median follow-up periods for men and women were 10.3 and 16.2 years, respectively. We estimated hazard ratio (HR) and 95% confidence interval (CI) using Cox proportional hazards models. RESULTS: After adjustment for suspected confounders, the multivariable-adjusted HRs for the highest versus lowest quintiles for total, CVD, stroke and CHD mortality among men were 0.83 (95%CI = 0.76, 0.90), 0.73 (95%CI = 0.63, 0.85), 0.71 (95%CI = 0.58, 0.88), 0.66 (95%CI = 0.47, 0.91), accordingly. Women with the highest intake had significantly 17% (HR = 0.83; 95% CI = 0.77, 0.90), 20% (HR = 0.80; 95% CI = 0.70, 0.92), and 28% (HR = 0.72; 95% CI = 0.59, 0.86) lower risks of total, CVD and stroke mortality compared with those of women with lowest Vitamin B6 intake. No significant association was observed between dietary Vitamin B6 and cancer mortality both among men and women. CONCLUSIONS: In the current study with two prospective Chinese cohorts, high dietary Vitamin B6 consumption was inversely associated with risk of all-cause and CVD mortality.
Multimodal characterization of a novel mutation causing vitamin B6-responsive gyrate atrophy.[Pubmed:29757052]
Ophthalmic Genet. 2018 Aug;39(4):512-516.
PURPOSE: Gyrate atrophy (GA) is a rare chorioretinal degeneration that results in the deterioration of night and peripheral vision, eventually leading to blindness. The disorder is caused by mutations in the gene encoding ornithine aminotransferase (OAT), causing increased levels of plasma ornithine. Treatment revolves around lowering plasma ornithine levels, with Vitamin B6 supplementation being the preferred treatment. Nevertheless, most patients do not respond to this therapy. Here, we report a rare case of Vitamin B6-responsive GA caused by a novel mutation in OAT and characterize the presentation with multimodal imaging. METHODS: This is a single-patient case report with a clinical diagnosis based on history, multimodal retinal imaging, laboratory findings, and DNA sequencing analysis. We include a 3D structure prediction of the novel mutant protein. RESULTS: DNA sequencing analysis demonstrated that there is a homozygous, novel variant c.473A>C: p.Y158S in OAT. Upon undergoing two weeks of Vitamin B6 supplementation, the patient exhibited a 28.5% reduction in plasma ornithine levels. In a follow-up visit two years later, plasma ornithine levels were reduced by 24.1% from the levels at initial presentation and disease progression was retarded based on clinical findings. CONCLUSION: One novel homozygous missense mutation in OAT was identified and considered to be pathogenic in a patient with GA. The response for the Vitamin B6 supplementation was positive, which is rare in all the GA cases reported in the literature. Our data suggests that further studies regarding the relationship between genotype and responsiveness to Vitamin B6 should be conducted.
Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases.[Pubmed:29737502]
Drug Saf. 2018 Sep;41(9):859-869.
INTRODUCTION: In the literature, Vitamin B6 has been linked to the development of polyneuropathy. Most often, these complaints were seen when taking high doses of Vitamin B6 for a long time. Evidence as to whether a lower dosage range of Vitamin B6 (< 50 mg/day) can also induce neuropathy is scarce. OBJECTIVE: We aim to comprehensively describe the cases of neuropathy associated with Vitamin B6 received by the Netherlands Pharmacovigilance Centre Lareb and to assess the case series concerning the use of Vitamin B6 and neuropathic complaints. METHODS: We describe the number and nature of the reported cases, including suspect product, dosage, duration of use, and Vitamin B6 serum levels. In addition, we describe the causality for the individual cases (Naranjo Probability Scale) and for the entire case series (Bradford Hill criteria). RESULTS: In total, 90 reports on products containing Vitamin B6 included at least one adverse drug reaction in the standardized Medical Dictionary for Regulatory Activities (MedDRA((R))) query (SMQ; broad) 'peripheral neuropathy'. The amount of Vitamin B6 in the products varied between 1.4 and 100 mg per tablet. The serum Vitamin B6 level was known in 36 cases (88-4338 nmol/l), and the mean serum Vitamin B6 level was 907 nmol/l. However, no statistical correlation between dosage and Vitamin B6 blood levels was found. DISCUSSION AND CONCLUSION: Causality assessment of the case series of 90 reports to Lareb shows it is plausible for the Vitamin B6 supplements to have caused complaints such as neuropathies. This is especially the case with higher dosages and prolonged use, but dosages < 50 mg/day also cannot be excluded.